You are on page 1of 17

2010 (

. . . )
.

, ,
Nanosystems, Nanomaterials, Nanotechnologies
2010, . 8, 4, . 749765

PACS numbers: 81.16.Be, 87.19.xj, 87.64.Bx, 87.85.J-, 87.85.Qr, 87.85.Rs, 87.85.St

, -
. . , . . , . . , . . ,
. . *, . . *, . . **, . . **,
. . **, . . ***, . . ***
. . . ,
. , 17,
03164 ,
*
,
. . . ,
. , 45,
03022 ,
**
. . . ,
. . , 36,
03680, , -142,
***
,
. , 47,
03680, , ,
, ( - ), in vitro MCF-7.
, CD 95 .
,
( MCF-7).
,
.
, . 749

750

. . , . . , . .

, .
, (
- ), - in vitro MCF-7. , CD 95 .
,

( MCF-7). , .

, .
, .
The complex of experiments directed to the development of the scientific basis
of chemical construction of multilevel biocompatible polyfunctional nanocomposites with hierarchical architecture (models of biomedical nanorobots), a
study of their physical and chemical properties, bioactivity in vitro on the cell
lines MCF-7 is completed. The processes of surface immobilization of biologically active nanocomposites of molecules with cytotoxic properties and monoclonal antibodies CD 95 with immunotherapeutic and sensory properties are
studied. The possibilities of targeted delivery of pharmaceuticals are verified
using the detection abilities of monoclonal antibodies. The influence of the
synthesized models of nanorobots on the cancer cells of human breast carcinoma (MCF-7 line) is analysed. The main results of the research work are described for the estimation of the current state of development and the prospects of its practical usage. In order to solve the problems of the targeted delivery of therapeutic drugs for the method of neutron-capture therapy, the
magnetosensitive boron-containing nanocomposites have been synthesized.
The technique of magnetosensitive nanostructures synthesis on the base of
gadolinium-containing nanocrystalline magnetite is developed.
: , , , , , .
( 19 2010 .)

1.
.
-

751

, .
,
, , , . ,
,
..
,

.
, , , ,
- ,
, , .. [1].

.
, : , ,

, .
, , .

, , , , -, -
. . , , - .
. , , ,

752

. . , . . , . .

. - ,
[2].
, , , . ,
,
.

; , -
; in vivo.
2.
2.1.


. - , , , ,
.
,
, , 60 . (),
,
.
. , , .

, , . , , ,

753



,

.

, ,
.
,







,
.

N,N--
-

[7, 8].


2 [3
3].

KI
,

:
B 2 + 2KI I2 + 2KBr , I2 + 2Na2S2O3 2Na
Br
aI + Na2S4O 6.


,
-NH2

.



:



--.



-
.




754

.
.
, . .

, . .

,

-.




1037 1
1130 1



S
SiSi.




4501010


2
24 /

[4].





-,


,
.


Ca//P = 1,7,



,


.

Fe2p-/Fe3pF
-
4 (



,,

30%).

/
,

,

,

755

2.2.
. ,
. , , (), . , , , . 10, 20, 30 . , [3].
. , ( Pt2+)
Fe3O4/ 128 /,
Fe3O4/- = 98,3 /, Fe3O4/ = 60,1 /. 23 .
-
-115 1 ,
.
, 265,9, : [5].
CD 95 .
,
,
. ().
, , Fc ,
Fab .
()
D 95
: / (Fe3O4/), / (Fe3O4/-), /
(Fe3O4/). D 95 Fas- IgG1, kappa, DX2 DakoCytomation ().
NaIO4 :

756

.
.
, . .

, . .

,
,









Synergy H
HT, Model
SIAFRTD
D, Serial Number
N
202
2993 (Bio Tek)
T

.


(Coom
massie Blue)) G-250

595


(. 1).

NH2-
.



.
,


Fee3O4,


.
1.



CD 95.

F 3O4/ + D
Fe
95
Fe3O4/-A + D 95
Fee3O4/ + D 95
Fe3O4/-A + D
95.
Fe3O4/ + D
D 95.

0, /

20
0,00
20
0,00
20
0,00
3,,88
3,,88

(D 95),, /
590

1,2

2,3

137,7

163,2

757

Fe3O4/
,
. 2+ , 24 .
, . pI .
Fe3O4/, , ,
D 95 , , Fc ,
Fab .
. . .
.
2,7 . ,
.
, , , , ,
. , .
, . [6, 7].
2.3.
, ( ), F-7.


[3, 4].
in vitro.
: ;

758

. . , . . , . .

2. .

, %

, %

, %

Fe34

100

98

Fe34/-

100

88

Fe34/

100

99

Fe34/

100

100

= 2,5 /, 25; CD 95 = 0,2 / (,


, 1030 /).
/
(Fe3O4/), /- (Fe3O4/-), / (Fe3O4/) (. 2).
,

CD 95,
( 1,5 ) (. 3).
. ,
,
CD 95 57% ,
50%.
. -,
. , ,
. , .
,
-, , , , . -,
.
, , [3, 4].

25

10
40

()

CD 95

+CD 95

31

20
46

38

21
57

48

27
57

Fe34/
Fe34/
Fe34/
Fe34/
Fe34/
Fe34/
Fe34/
Fe34/
Fe34/

-++
++
++
+ +CD 95
+ +CD 95
-+ -+CD 95
+CD 95
+CD 95
+CD 95

, %

3. .

,
759

760

. . , . . , . .

, (),
CD 95,

,
.
2.4.
10B, 157Gd
. -,
17% ,
: - 7Li.
, 10B 47 , , , ,
, .
157Gd (255000 )
, (98%) -.
, .
10 157Gd
. , -2,3-
; .
-2,3- .

,

. -2,3- (DMSA)
, ,
.
DMSA
. , DMSA, -

761



,


. in
vivo



DMSA
A,

( 32,5
5%)

).


DMSA
A





.
,
DMSA

.










,

-2, 3-


DM
MSA :

DMSA
A
,




,


.


, DMSA,

(3
11)


.


DMSA
D

,

-
-

. ,

,, S
SH-

762

. . , . . , . .

4. -
Fe3O4DMSA/ .
-,
-,
, /
,

40,3
9,84
0,129
40,5

0,0024 / = 2,4 /. S. = 130 2/ SH 0,019 /2.



-.
-
, .
- .
Fe3O4DMSA/ -, . 4.
= 7,
, .
, -
COOH- SH- .
.
()
,
.
DMSA
, ,
.
DMSA -
- . ()

:

763



6
9.



SS-
..


.
Gd-



,



, -



(
),


10.

157Gd
d,

(
,

) , ...

,
.
,



1980-



Gd-

23
.
-

.


:
FeSO4 + FeCl3 + Gd(NO3)3 FeGdO3FeO.
F




, -

764

. . , . . , . .

. , .

. , (., 1).
, , .
= 9001000 (., 2)
20 30,
GdFeO3 (JCPDS 47-67).

, ,
GdxFe3xO4, .
,
GdFeO3.
3.

( -
), - in vitro .
, (-, , ), -

765

.
( MCF-7). : , , .

1.

2.
3.
4.

5.
6.
7.

M. C. Roco, R. S. Williams, and P. Alivisatos, Nanotechnology Research Directions. Vision for Nanotechnology R&D in the Next Decade (Dordrecht: Kluwer
Academic Publishers: 2002).
L. Levy, Y. Sahoo, Kyoung-Soo Kim, and J. Earl Bergey, Chem. Mater., 14:
3715 (2002).
(. . .
, . . ) (: : 2007), . 1.
Nanomaterials and Supramolecular Structures. Physics, Chemistry, and Applications (Eds. A. P. Shpak and P. P. Gorbyk) (Dordrecht, Netherlands: Springer:
2009), p. 63.
. . , . . , . . , . . , . .
( 81734 25.01.2008 ).
. . , . . , . . , . . (
86322 10.04.2009 ).
. . , . . , . . , . . , . . , . . ( 91149 25.06.2010 ).